SAT0260 Biomarkers Associated with Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate with Changes in Clinical Response in Subjects Treated with Mavrilimumab at Doses above 10 Mg

Background Mavrilimumab is a human monoclonal antibody targeting the alpha subunit of GM-CSF receptor and was recently evaluated in RA subjects in a phase 2a study (EARTH). Results reported from the European (EU) cohort demonstrated that mavrilimumab shows activity in subjects with moderate to sever...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.687
Hauptverfasser:	White, W., Ryan, P.C., Guo, X., Sinibaldi, D., Ranganna, G., Godwood, A., Saurigny, D., Close, D., Eck, S., Wilkins, D., Roskos, L., Sleeman, M., Li, W., Cavet, G., Defranoux, N.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!